A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

Part of paid clinical trials in San Antonio, Texas.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07422298
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • BMS-986278 — DRUG
    Specified dose on specified days
  • Placebo — DRUG
    Specified dose on specified days
  • Moxifloxacin — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.

Key Dates

Start date
Feb 19, 2026
Status verified
Mar 2026
Primary completion
Jun 15, 2026
Completion
Jun 15, 2026

Study Design

Enrollment
32 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment A
  • Experimental: Treatment B
  • Placebo Comparator: Treatment C
  • Experimental: Treatment D

Primary Outcome Measure

Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF) [ Time Frame: Up to Day 13 ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
Worldwide Clinical TrialsSan AntonioTexas78217
Alan Hand, Site 0001
210-635-1515

Find similar trials in San Antonio, TX

By research site
Worldwide Clinical Trials· San Antonio, TX

Related Studies